NU-MED Group
NU-MED Group (Affidea NU-MED) is a Polish oncology healthcare provider operating four regional cancer centers delivering radiotherapy, brachytherapy, chemotherapy, PET-CT, and clinical trials, primarily funded by NFZ public-payer contracts.
- Company typePrivate
- Founded2005
- HeadquartersGdansk, Poland
- Headcount1–10
- GTM typeB2C
- OfferingServices
What NU-MED Group does
NU-MED Group (legal name: NU-MED Grupa S.A., operating as Affidea NU-MED) is a Polish oncology healthcare provider operating four regional cancer centers in Elbląg, Katowice, Tomaszów Mazowiecki, and Zamość, plus satellite clinics for mammography and oncology consultations in Ostróda, Iława, and Działdów. Core services include external-beam radiotherapy (3D-CRT, IMRT, VMAT, SBRT, IGRT with DIBH), HDR brachytherapy (Flexitron, MicroSelectron), chemotherapy, oncological surgery (via partner hospitals), diagnostic imaging (MRI, CT, PET-CT, mammography with tomosynthesis), clinical trials, and 26 NFZ-funded specialized drug programs; advanced equipment includes Varian TrueBeam, Elekta Versa HD, Elekta Synergy, Gamma Knife Perfexion, and GE 512-slice CT. The Katowice center holds the first M.D. Anderson accreditation in Poland and ISO 9001:2015 certification, while the group operates academic research partnerships with Śląski Uniwersytet Medyczny and Uniwersytet Medyczny w Poznaniu, including CAR-T cell therapy work and the GLIOMED glioblastoma molecular diagnostics project.
The business model is overwhelmingly NFZ-funded: Narodowy Fundusz Zdrowia contracts cover radiotherapy, brachytherapy, chemotherapy, diagnostic imaging, drug programs, and oncological consultations at no cost to patients, with patients accessing services via physician referrals, self-referral to oncology clinics, or the Szybka Terapia Onkologiczna (DILO) rapid-treatment package. A secondary commercial stream offers paid MRI/CT/mammography examinations at transparent unit prices (e.g., MRI head PLN 550, CT head PLN 350) for uninsured patients or those seeking specific diagnostics. Patient acquisition relies on NFZ referral networks, regional hospital partnerships (e.g., Wojewódzki Szpital Zespolony w Elblągu, Szpital Wojewódzki w Zamościu), community screening events, and KPO-funded national preventive-educational actions, with patient engagement handled through a digital portal, e-services, and press offices at each facility.
The group is a wholly-owned subsidiary of Affidea, the pan-European diagnostic and oncology network, following a 2023 rebranding; prior institutional backing came from Enterprise Investors, a leading Central European PE firm. The affiliated Fundacja Affidea NU-MED (KRS: 0000662419) supports cancer prevention and patient advocacy. Management oversight sits with a Warsaw-based Biuro Zarządu, with operational leadership distributed across the four centers. NU-MED does not disclose revenue or headcount publicly; the firmographics-reported 1-10 employees is internally inconsistent with four multi-bed hospitals and is interpreted as corporate-office headcount only.
NU-MED Group firmographics
Firmographics- Name
- NU-MED Group
- Legal name
- NU-MED Grupa S.A.
- Website
- https://nu-med.pl
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NU-MED Group (Affidea NU-MED) is a Polish oncology healthcare provider operating four regional cancer centers delivering radiotherapy, brachytherapy, chemotherapy, PET-CT, and clinical trials, primarily funded by NFZ public-payer contracts.
- Ownership category
- akta.pro rank
NU-MED Group industry classification
Industry- Product category
- Oncology Healthcare Services
- NAICS
- Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Offices of Physicians (62111)
- SIC
- Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Oncology & Cancer Specialty Hospitals (HLAFAHAC)
- akta.pro secondary industries
- Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Radiation Oncology (HLAKAFAC)
Keywords
Where NU-MED Group is headquartered
LocationHeadquarters
- HQ city
- Gdansk
- HQ country
- Poland
- HQ region
- Europe
Offices6 records
Markets served
NU-MED Group business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- NFZ Contracted Healthcare Services: All medical services are primarily funded through contracts with Narodowy Fundusz Zdrowia (NFZ), Poland's national health fund. Services covered include radiotherapy, brachytherapy, chemotherapy, diagnostic imaging (MRI, CT, PET-CT), oncological consultations, and drug programs. All NFZ-covered services are free for patients.
- Commercial/Private Medical Services: The group also provides paid medical services outside of NFZ coverage, including diagnostic imaging, consultations, and full oncological treatment for patients without public insurance or seeking specific services. Pricing is set per examination type.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | MRI without contrast - various body regions |
| Unit Pricing | Pay-as-you-go | MRI with contrast - various body regions |
| Unit Pricing | Pay-as-you-go | CT without contrast - various body regions |
| Unit Pricing | Pay-as-you-go | CT with contrast - various body regions |
| Unit Pricing | Pay-as-you-go | Mammography pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
NU-MED Group product offering
Product offeringCore offering
NU-MED Group operates a network of four oncology centers across Poland providing comprehensive cancer care including external-beam radiotherapy (3D-CRT, IMRT, VMAT, SBRT, IGRT), HDR brachytherapy, chemotherapy, oncological surgery, and diagnostic imaging (MRI, CT, PET-CT, mammography). Services are delivered through NFZ (Polish National Health Fund) contracts as well as commercial fee-for-service channels, supported by clinical trials, drug treatment programs, psycho-oncological care, and an electronic patient portal.
Product overview
NU-MED Group is a network of oncology healthcare facilities operating under the Affidea brand, providing comprehensive cancer diagnosis and treatment services across Poland. The portfolio consists of four main facilities: Centrum Radioterapii i Onkologii in Elbląg (radiotherapy, brachytherapy, diagnostic imaging including MRI and CT), Centrum Diagnostyki i Terapii Onkologicznej in Katowice (advanced radiotherapy with Gamma Knife and IGRT, first Polish M.D. Anderson-accredited center), Specjalistyczny Szpital Onkologiczny in Tomaszów Mazowiecki (radiotherapy, chemotherapy, brachytherapy, clinical trials), and Centrum Diagnostyki i Terapii Onkologicznej in Zamość (PET-CT, radiotherapy). Core services include radiotherapy (teleradiotherapy and brachytherapy), clinical oncology (chemotherapy), oncological surgery, diagnostic imaging (MRI, CT, PET-CT, mammography), clinical trials, and NFZ-funded drug treatment programs. The group also provides preventive health programs, psycho-oncological support, dietary counseling, and e-services including patient portal and electronic forms. Treatment is primarily funded through NFZ (National Health Fund) contracts with some commercial services available.
Differentiator
Problem solved
Functional benefit
Products and services
- Radiotherapy (Radioterapia) Primary cancer treatment method using ionizing radiation to destroy cancer cells, delivered via teleradiotherapy (3D-CRT, IMRT, VMAT, SBRT, IGRT) and brachytherapy. Includes advanced DIBH technique to reduce cardiac dose during breast radiotherapy. Available to oncology patients across NU-MED centers under NFZ contracts and commercially.
- Brachytherapy (Brachyterapia) High-dose-rate radiation therapy placing radioactive sources directly at or near the tumor site for precise treatment of gynecological, prostate, breast, and skin cancers. Delivered via Flexitron (Ir-192) at Elbląg and MicroSelectron at Katowice.
- Clinical Oncology / Chemotherapy (Onkologia Kliniczna) Cancer treatment via administration of cytostatic drugs, delivered in inpatient and day-care settings across NU-MED facilities. Includes 38 chemotherapy chairs at Tomaszów Mazowiecki and 26 NFZ specialized drug programs covering GIST, liver cancer, soft tissue sarcomas, ovarian cancer, and others.
- Oncological Surgery (Chirurgia Onkologiczna) Surgical intervention for cancer treatment, delivered in coordination with regional partner hospitals (Wojewódzki Szpital Zespolony w Elblągu, Samodzielny Publiczny Szpital Wojewódzki in Zamość). One of three pillars of comprehensive oncology care alongside radiotherapy and chemotherapy.
- Diagnostic Imaging (Diagnostyka Obrazowa) Cancer diagnosis and monitoring imaging services including MRI (OPTIMA MR 1.5T and MAGNETOM Sola 1.5T with BioMatrix), CT (GE Revolution VIBE 512-slice), PET-CT (in Zamość under NFZ contract), and mammography (Mammomat Inspiration 3D with tomosynthesis). Available on NFZ and commercial fee-for-service basis.
- Gamma Knife Perfexion Radiosurgery Intracranial radiosurgery system with 192 cobalt-60 sources delivering sub-millimeter (0.15 mm) accuracy. Provided at NU-MED Katowice in partnership with Voxel Gamma Knife for treatment of brain metastases, meningiomas, nerve tumors, trigeminal neuralgia, and pituitary adenomas.
- Clinical Trials (Badania Kliniczne) Clinical research programs offering patients access to experimental treatments and cutting-edge therapies (e.g., CAR-T cell therapy collaboration with Medical University of Poznań, GLIOMED molecular diagnostics project with Medical University of Silesia) when standard therapies have not produced desired outcomes.
- Drug Treatment Programs (Programy Lekowe) NFZ-funded treatment programs using innovative, expensive pharmaceutical substances for defined patient groups with specific disease entities. Includes 26 specialized drug programs at Tomaszów Mazowiecki covering GIST, liver cancer, soft tissue sarcomas, ovarian cancer, and other rare oncology indications.
- Preventive Health Programs (Programy Profilaktyczne) Cancer screening programs including breast cancer mammography (free under NFZ for women aged 45–74 every two years), melanoma/dermatoscopy prevention (510 free examinations funded by Łódź Voivodeship Budget), colorectal screening colonoscopy (660 enrolled participants in Łódź Voivodeship), and lung cancer screening.
- Oncology Clinic (Poradnia Onkologiczna) First-contact outpatient oncology clinic providing diagnostic evaluation, treatment planning, and ongoing care. Accessible at all NU-MED centers without requiring physician referral, supporting early diagnosis and Szybka Terapia Onkologiczna (DILO) pathway enrollment.
- Psycho-oncological Support (Wsparcie Psychologiczne) Specialized psycho-oncological care including individual psychotherapy, psychological counseling, emotional support, psychoeducation, and relaxation training for oncology patients and their families. Delivered by clinical psychology and psycho-oncology specialists across NU-MED facilities.
- Non-Oncological Radiation Treatment (Leczenie Nieonkologiczne) Radiotherapy for non-cancer conditions including heel spurs (approximately 70% effectiveness in three months), degenerative joint conditions, and Graves-Basedow orbitopathy. Delivered using the same linear accelerator infrastructure as the oncology service.
Quantifiable outcome
- Gamma Knife achieves sub-millimeter accuracy (0.15mm) in intracranial radiosurgery with over 1 million patients treated worldwide
- +2 more outcomes
Companies that use NU-MED Group
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
NU-MED Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
NU-MED Group partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, major and supporting.
- Tomaszowskie Centrum ZdrowiacoreStrategic partnership for comprehensive oncological care. Tomaszów Mazowiecki facility collaborates with Tomaszowskie Centrum Zdrowia for surgical procedures and complementary treatments, enabling patients to receive surgery within 200km of the main radiotherapy center.
- Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II w ZamościucorePartnership with regional hospital in Zamość provides comprehensive oncological care including oncological surgery, chemotherapy, and radiotherapy. The NU-MED facility houses the oncology clinic while the hospital provides surgical and inpatient services.
- Wojewódzki Szpital Zespolony w ElblągucoreJoint operation of Elbląskie Centrum Onkologii (Elbląg Oncology Center). NU-MED provides radiotherapy and diagnostic imaging while the regional hospital provides surgical oncology, chemotherapy, and comprehensive diagnostic services under the DILO (Rapid Oncological Therapy) package.
- Uniwersyteckie Centrum Kliniczne w KatowicachmajorPartnership with University Clinical Center in Katowice enables comprehensive oncological care including chemotherapy, SBRT stereotactic radiotherapy, radio surgery, and full diagnostic imaging services (PET/CT, MR, CT, RTG, mammography including spectral mammography).
- Śląski Uniwersytet Medyczny w KatowicachmajorAcademic partnership with Medical University of Silesia in Katowice. NU-MED staff conducts educational activities within the Department of Oncology and Radiotherapy. Joint research project GLIOMED for molecular diagnostics of glioblastomas.
- AffideacoreNU-MED Group operates under the Affidea brand, part of the pan-European Affidea healthcare network. This provides access to international best practices, shared standards, and pan-European brand recognition in diagnostic and oncological services.
- Fundacja NU-MED / Fundacja Affidea NU-MEDsupportingAffidea NU-MED Foundation supports health prevention, cancer awareness campaigns, and patient support. Patients can donate 1.5% of their income tax to the foundation (KRS: 0000662419). Foundation organizes charity events and supports patients in treatment.
- Amazonki (Breast Cancer Patient Association)supportingCollaboration with Amazonki breast cancer patient support groups to assist patients and their families in coping with cancer. Joint events and mutual support programs.
- Instytut Onkologii w GliwicachmajorPartnership with Oncology Institute in Gliwice for lymphoma treatment and CAR-T cell therapy collaboration. Enables access to advanced cellular therapies and bone marrow transplantation.
- Uniwersytet Medyczny w PoznaniumajorCollaboration with Medical University of Poznań for CAR-T cell therapy (TISEL study) in lymphoma treatment, providing access to cutting-edge cellular immunotherapy.
- Fundacja AliviasupportingPartnership with Alivia Cancer Foundation supporting cancer patients with information, advocacy, and access to innovative treatments and clinical trials.
- Fundacja Oko w Oko z RakiemsupportingPartnership with 'Eye to Eye with Cancer' Foundation for patient support and cancer awareness initiatives.
- Krajowy Plan Odbudowy i Zwiększania Odporności (KPO)majorEU-funded recovery plan providing financing for national preventive-educational actions, health infrastructure improvements, and patient support programs across NU-MED facilities.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
NU-MED Group competitors and assessment
Company assessmentDirect peers
- LUX MED: Largest Polish private healthcare network (owned by BUPA). Competes with NU-MED in outpatient oncology consultations, diagnostic imaging, and ambulatory treatment in overlapping Polish geographies with similar NFZ and B2B funding mix.
- Medicover: Major Polish private healthcare group offering integrated outpatient, diagnostic, and specialist services including oncology. Comparable to NU-MED as a multi-site Polish private provider serving NFZ-reimbursed and commercial patients with a similar one-stop care model.
- Enel-Med: Polish private outpatient and diagnostic healthcare network with growing oncology presence. Comparable to NU-MED in ambulatory oncology, diagnostic imaging, and NFZ contract structure across multiple Polish cities.
- GenesisCare: Largest private oncology services network globally (Australia, UK, Spain, US), specializing in radiation oncology, medical oncology, and integrated cancer care. Closest international analog to NU-MED's specialist oncology center model under multi-site private operator ownership.
- Scanmed: Polish private multi-specialty hospital and outpatient group with oncology and diagnostic imaging services. Comparable mid-sized Polish private operator with similar NFZ contract exposure and multi-region footprint.
Broad incumbents
- Affidea: Pan-European diagnostic and outpatient healthcare operator and parent of NU-MED. Overlaps heavily with NU-MED in imaging and ambulatory oncology across multiple European countries, but operates as a broad portfolio rather than a Poland-focused oncology specialist.
- Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie: Poland's flagship public oncology research institute operating comprehensive cancer centers in Warsaw and Gliwice. Direct comparator in advanced radiotherapy, clinical trials, and NFZ-funded oncology services, but with broader research mandate and public ownership.
Regional players
- Dolnośląskie Centrum Onkologii (DCO): Regional public oncology center serving Lower Silesia (Wrocław) with radiotherapy, chemotherapy, and diagnostic imaging. Comparable scale and service mix to NU-MED's individual centers, though regionally distinct and publicly owned.
- Swissmed: Polish private hospital and clinic group with oncology and radiotherapy capabilities, primarily serving the Tricity (Gdańsk) area. Comparable in clinical scope and patient mix to NU-MED's Elbląg center, with similar NFZ-plus-commercial funding model.
Emerging players
- Voxel: Polish diagnostic imaging operator and Gamma Knife service provider already partnering with NU-MED's Katowice center. Comparable in advanced imaging and radiosurgery, with overlapping NFZ PET/CT and radiotherapy offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
NU-MED Group social profiles
Digital presenceNU-MED Group compliance and trust
Trust signalCompliance2 records
NU-MED Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
NU-MED Group leadership team
Management profileNumber of profiles
Profiles3 records
NU-MED Group subsidiaries and ownership
Company hierarchySubsidiaries5 records
NU-MED Group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NU-MED Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NU-MED Group
What does NU-MED Group do?
NU-MED Group operates a network of four oncology centers across Poland providing comprehensive cancer care including external-beam radiotherapy (3D-CRT, IMRT, VMAT, SBRT, IGRT), HDR brachytherapy, chemotherapy, oncological surgery, and diagnostic imaging (MRI, CT, PET-CT, mammography). Services are delivered through NFZ (Polish National Health Fund) contracts as well as commercial fee-for-service channels, supported by clinical trials, drug treatment programs, psycho-oncological care, and an electronic patient portal.
Is NU-MED Group a public or private company?
NU-MED Group is a private company. It is classified as corporate owned and is currently operating.
When was NU-MED Group founded?
NU-MED Group was founded in 2005. It employs 1 to 10 people.
Where is NU-MED Group based?
NU-MED Group is headquartered in Gdansk, Poland, in the Europe region.
How does NU-MED Group make money?
Two revenue lines are on record. NFZ Contracted Healthcare Services are the primary driver. The others are commercial/Private Medical Services.
Who are NU-MED Group's main competitors?
Direct peers on record are LUX MED, Medicover, Enel-Med, GenesisCare and Scanmed. Broad incumbents are Affidea and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie. Regional players are Dolnośląskie Centrum Onkologii (DCO) and Swissmed. Voxel is listed as an emerging player.
Does NU-MED Group have an API?
No public API is recorded for NU-MED Group.
What industry is NU-MED Group in?
NU-MED Group's product category is Oncology Healthcare Services. Its primary akta.pro industry code is HLAFAHAC, Oncology & Cancer Specialty Hospitals, with a secondary code of HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation). Its NAICS code is 6223 and its SIC code is 8060.